New research published in the European Medical Journal on January 11, 2026, reveals a significant association between statin therapy and improved survival rates in critically ill patients suffering from acute kidney injury (AKI) following non-traumatic intracerebral hemorrhage (ICH). The large observational analysis of US critical care data, specifically from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, examined 1,805 adults diagnosed with both ICH and AKI. The study found that statin therapy administered in the intensive care unit was linked to a substantially lower risk of 30-day all-cause mortality, showing a 52% relative reduction in the risk of death (hazard ratio 0.48; 95% confidence interval 0.37–0.62, P < 0.001). Researchers carefully adjusted for baseline differences between statin users and non-users using propensity score matching and inverse probability of treatment weighting to ensure robust findings. These findings are corroborated by broader scientific literature. A 2023 systematic review and meta-analysis, for instance, concluded that statin treatment significantly decreased overall mortality in critically ill surgical patients with AKI, reporting an odds ratio of 0.73 (95% CI: 0.69–0.77; p<0.001). Another retrospective cohort study from 2016 also indicated that statin use was associated with lower mortality (hazard ratio, 0.74; 95% CI, 0.69, 0.79) and a reduced risk of all-cause rehospitalization in AKI survivors with chronic kidney disease (CKD). More recently, a 2025 study on hospitalized CKD patients similarly highlighted a reduced risk of in-hospital AKI and mortality with statin use, noting particularly favorable renoprotective effects from atorvastatin. While some earlier reviews in 2018 indicated equivocal results and insufficient evidence for routine kidney protection by statins, the cumulative and recent evidence, including this EMJ study, strengthens the case for their potential benefits in specific AKI patient populations. The study underscores the importance of thoughtful, individualized clinical decision-making regarding statin initiation or continuation in ICU patients with ICH-AKI for potentially better short-term survival.